checkAd

    DGAP-News  120  0 Kommentare Medios AG continues record course: Strong growth in the first half of 2022

    DGAP-News: Medios AG / Key word(s): Half Year Report/Half Year Results
    Medios AG continues record course: Strong growth in the first half of 2022

    11.08.2022 / 07:37
    The issuer is solely responsible for the content of this announcement.


    Press release

     

    Medios AG continues record course: Strong growth in the first half of 2022

     

    • Revenue increase of around 25% – Strong inorganic and organic growth
    • Profit margins significantly and sustainably improved, sixth consecutive record quarter
    • Operating cash flow positive in both the second quarter of 2022 and the first half of 2022
    • Forecast for the 2022 financial year confirmed despite continuing global uncertainties, revenue expected to be in the upper range of the guidance

     

    Berlin, August 11, 2022 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, continued its dynamic growth in the first half of 2022. Consolidated revenue in the period from January to June rose by 24.8% to €792.2 million compared to the same period of the previous year (previous year: €634.9 million). EBITDA pre1 increased disproportionately by 55.9% to €28.5 million (previous year: €18.3 million) with a corresponding higher margin of 3.6% (previous year: 2.9%). Revenue and earnings thus reached new record levels. Both operating segments contributed to the growth in revenue and earnings. Based on the strong business development, Medios has confirmed its revenue and earnings guidance for the full year 2022. The Company expects revenue to reach the upper end of the communicated range of €1.45 – 1.6 billion.

    The Medios Group's revenue growth of around 25% in the first half of the year is largely attributable to inorganic growth from the integration of the NewCo Pharma Group (sixteen percentage points). Organic growth accounted for nine percentage points. With the acquisition of NewCo Pharma Group, Medios has in particular strengthened the Patient-Specific Therapies segment.

    In the first half of 2022, cash flow from operating activities amounted to €10 million and was impacted by the strategic build-up of inventories. For the second half of 2022, Medios thus expects corresponding positive effects on cash flow from the reduction of inventories.

    Seite 1 von 5


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Medios AG continues record course: Strong growth in the first half of 2022 DGAP-News: Medios AG / Key word(s): Half Year Report/Half Year Results Medios AG continues record course: Strong growth in the first half of 2022 11.08.2022 / 07:37 The issuer is solely responsible for the content of this announcement. Press …

    Schreibe Deinen Kommentar

    Disclaimer